Skip to content
Upcoming events
AEEDC Dubai 202719–21 January 2027World Health Expo (WHX) Dubai 202725–28 January 2027ChinaDental South China 20273–6 March 2027GermanyIDS 2027 — International Dental Show16–20 March 2027United StatesAAD Annual Meeting 202719–23 March 2027Dubai Derma 20276–8 April 2027Dental-Expo Moscow Spring 202726–29 April 2027France7th World Congress of Dermoscopy12–15 May 2027GermanyEADV Symposium 202720–22 May 2027United StatesASCO Annual Meeting 20274–8 June 2027ChinaSino-Dental 20279–12 June 2027White Nights 2027 — St. Petersburg International Oncology ForumUsually early JulyArmenian Medical World Congress 20278–10 July 2027Dental-Expo Moscow 2027Usually late SeptemberNetherlandsEADV Congress 202722–25 September 2027SpainEAO Congress 202723–25 September 2027CanadaCFAS Annual Meeting 202723–25 September 2027Russian Health Care Week 2027Usually December
Oncology

Adding pembrolizumab to SBRT fails to improve outcomes in early lung cancer, phase 3 trial stopped

Close-up of a patient consulting a doctor with a clipboard in a medical setting.

Key facts

  • A phase 3 trial tested adding the immunotherapy pembrolizumab to stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer.
  • The combination did not improve event-free survival, and the trial was stopped early.
  • The idea came from a promising phase 2 result — a reminder that early signals often do not hold up.

What happened

A phase 3 trial combining the immune checkpoint inhibitor pembrolizumab with stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC) failed to improve event-free survival compared with SBRT alone, and was halted early. The combination had been built on an encouraging phase 2 signal, which did not translate into benefit in the larger, definitive study.

Why it matters

SBRT — highly focused, high-dose radiotherapy given in a few sessions — is a standard option for people with small lung cancers who cannot have surgery or prefer not to, often because of age, heart disease or chronic lung disease. Some of these cancers come back later, so researchers hoped that adding immunotherapy, which is already effective in more advanced lung cancer, would lower the risk of recurrence.

The negative result means SBRT alone remains the standard for this group outside clinical trials. It also spares patients the cost and potential side effects of immunotherapy, such as inflammation of the lungs, bowel or thyroid, when it does not help.

Background: why phase 2 results can mislead

Phase 2 trials are smaller, often have fewer events and may compare against historical data rather than a randomised control group. Promising differences in these settings frequently shrink or disappear in phase 3. That is why treatment guidelines rely on large randomised trials before changing practice.

What it means for clinicians and students

  • Clinicians: continue to offer SBRT alone for medically inoperable early NSCLC, and consider clinical trials for patients interested in new approaches.
  • Patients: if you are having SBRT, ask your oncologist about follow-up imaging and how recurrences are detected and treated.
  • Dental and surgical teams: many of these patients are older and have heart and lung disease — plan procedures with this in mind.
  • Students: a textbook example of why phase 2 signals need confirmation in phase 3 trials.

Source: Medscape Medical News